BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:2025 marks an exciting phase for covalent drugs\, with the fie
 ld doubling down on de-risked assets and tackling high-value targets in o
 ncology\, immunology\, and beyond. With MOMA Therapeutics recently dosing
  their first patient with a covalent Werner helicase inhibitor\, and Nova
 rtis partnering with covalent pioneer Matchpoint Therapeutics in a $60 mi
 llion deal\, it's clear that the therapeutic potential of covalency is gr
 owing.\n\nThe 3rd Covalent Drug Discovery and Development Summit returns 
 as the premier industry forum for experts to accelerate the discovery\, t
 ranslation and development of covalent drugs\, driving the next wave of f
 irst- and best-in-class therapeutics against previously undruggable targe
 ts.\n\nUniting covalent drug leaders from the likes of Vividion Therapeut
 ics\, Pfizer\, Revolution Medicines and Frontier Medicines\, this three d
 ay deep-dive forum will focus on:\n\n- Optimizing warhead selectivity\, r
 eactivity and durability to ensure the development of tolerable\, potent 
 covalent therapies- Targeting non-cysteine residues and hard-to-drug prot
 eins including transcription factors to expand the druggable proteome- El
 ucidating PK/PD relationships and understanding ADME and target engagemen
 t to inform dosing and streamline clinical development- Innovating advanc
 ed screening technologies and lead optimization strategies to rationally 
 triage hits and progress covalent candidates efficiently\n\nOver 3 days\,
  join 80+ leaders in medicinal chemistry\, biochemistry\, structural biol
 ogy and translation to uncover insights on overcoming key challenges in w
 arhead design\, lead optimization and preclinical to clinical development
 \, ensuring that your pipeline is de-risked to reach patients in need.\n\
 nURLs:Website: https://go.evvnt.com/3238904-0?pid=185Tickets: https://go.
 evvnt.com/3238904-2?pid=185Brochure: https://go.evvnt.com/3238904-3?pid=1
 85\n\nPrices:Drug Developer Pricing - 3 Day Pass (Conference + Workshop D
 ay): USD 4197.00\,Drug Developer Pricing - 3 Day Pass (Conference + 1 Wor
 kshop): USD 3598.00\,Drug Developer Pricing - 2 Day Pass (Conference Only
 ): USD 2999.00\,Academic and Not-for-Profit Pricing - 3 Day Pass (Confere
 nce + Workshop Day): USD 3597.00\,Academic and Not-for-Profit Pricing - 3
  Day Pass (Conference + 1 Workshop): USD 3098.00\,Academic and Not-for-Pr
 ofit Pricing - 2 Day Pass (Conference Only): USD 2599.00\,Service and Sol
 ution Provider Pricing - &nbsp\;3 Day Pass (Conference + Workshop Day): U
 SD 5097.00\,Service and Solution Provider Pricing - 3 Day Pass (Conferenc
 e + 1 Workshop): USD 4398.00\,Service and Solution Provider Pricing - 2 D
 ay Pass (Conference Only): USD 3699.00\n\nSpeakers: Andreas Goutopoulos\,
  CEO\, actithera\, Brendan Hilbert\, Director of Protein and Structural S
 ciences\, Antares Therapeutics\, Brian Cook\, Vice President and Head of 
 Early Discovery Chemistry\, Vividion Therapeutics\, Chris Haggard\, Co-Fo
 under and CTO\, Axiom Therapeutics\, Daniel Nomura\, Professor - Chemical
  Biology and Molecular Therapeutics\, University of California at Berkele
 y\, Daniele Canzani\, Senior Scientist\, Talus Bio\, Fiona Pachl\, Associ
 ate Principal Scientist - Chemical Biology and Proteomics\, AstraZeneca\,
  Ivan Cornella-Taracido Chief Scientific Officer\, Covant Therapeutics\, 
 Jacob Stuckey\, Vice President - Biochemistry and Chemical Biology\, Flar
 e Therapeutics\, Jared Cumming\, Chief Scientific Officer\, Matchpoint Th
 erapeutics\, John (Jianwei) Che\, Core Director\, Dana-Farber / Harvard C
 ancer Center\, Lata Jayaraman\, Head Senior VP\, Oncology and Inflammatio
 n Research\, Frontier Medicines\, Laura D'Agostino\, VP Chemistry\, Monim
 oi Therapeutics\, Markus Schirle\, Executive Director\, Novartis AG\, Mat
 thew Labenski\, Senior Director - Proteomics and Chemical Biology\, Jnana
  Therapeutics\, Ning Deng\, Director\, IMTAC Discovery\, BridGene Bioscie
 nces Inc.\, Paramita Deria\, Discovery Chemistry Professional\, Bayer\, S
 ean Toenjes\, Executive Director\, Chemistry and Innovation\, Aethon Ther
 apeutics\, Sujata Chakraborty\, Senior Scientist\, Revolution Medicines\,
  Tangpo Yang\, Principal Scientist\, Pfizer\, Uthpala Seneviratne\, Assoc
 iate Principal Scientist\, AstraZeneca\n\nCategory: Conferences | Science
 \, Health and Medicine | Pharmaceuticals | Drug Development\n\nDate and T
 ime: 9th December 2025 at 9:00 am to 11th December 2025 at 3:15 pm\n\nVen
 ue details: Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, Mas
 sachusetts\, 02116\, United States\n
DTEND:20251211T151500
DTSTAMP:20260512T223117Z
DTSTART:20251209T090000
LOCATION:Revere Hotel Boston Common\, 200\, Stuart Street\, Boston\, Massa
 chusetts\, 02116\,
SEQUENCE:0
SUMMARY:2025 marks an exciting phase for covalent drugs\, with the field d
 oubling down on de-risked assets and tackling high-value targets in oncol
 ogy\, immu...
UID:9bc2eb1f-828d-4282-b991-ddc55dbd5ee9
END:VEVENT
END:VCALENDAR